Register for the Let’s Talk About Biomarker Testing: With MyTumorID, I Decide Webinar

Join us for an informative MyTumorID webinar featuring an expert in the field who will explain what biomarker testing is, how it influences treatment planning and access to clinical trials, and why it matters. You’ll also hear from a patient about how biomarker testing results impacted their brain tumor experience. This educational webinar will conclude with a moderated discussion of questions submitted by the audience.

Meet Our Speakers

Serendipity Zapanta Rinonos, M.D., Ph.D.

Dr. Serendipity Zapanta Rinonos is a board-certified neurologist and scientist, specializing in the care of adult patients with primary brain tumors. Besides her clinical practice at the University of Florida, she is also principal investigator of an independent laboratory, The Serendipity Laboratory, in the UF Dept. of Neurosurgery.  The mission statement of her laboratory is to harness epigenetics and molecular biological phenomena to develop innovative, targeted molecular therapeutics for malignant brain tumors.  In her career thus far, she has obtained several competitive grants at UCLA and UF, most recently as a top-scoring K12 scholar at UF, as well as a provisional patent while at UCLA for her fellowship training. 

Dr. Rinonos strives to provide a “therapeutic educational experience” for patients at every visit. She aims to meet every patient where they are conceptually, guiding them into a true understanding of their diagnosis and treatment options so that they feel empowered to make informed decisions about their care.

In her free time, Dr. Rinonos engages in creative expression as a lifelong concert violinist, award-winning writer, and artist.  She enjoys drawing and painting, playing in musical ensembles with her family, and learning multiple languages.

Catherine (“Cathy”) Dearlove

Cathy is a long-term brain cancer survivor, a busy corporate litigator and the proud mother of two daughters. In May 2011, while building her law practice and raising two young daughters, Cathy’s doctor said the words ‘you have a brain tumor’ from an incidental finding on an MRI.

After surgery to remove the tumor, pathologists initially classified Cathy’s tumor as a Grade 2 oligodendroglioma, and she was told that recurrence was likely. In 2012, Cathy enrolled in a clinical research study at the National Institutes of Health, known as the “Natural History Study.” In 2017, six years after her surgery, Cathy’s tumor was reclassified as a grade 2 astrocytoma following additional biomarker testing and updates to the World Health Organization classification system. As the study ended in 2025, Cathy was told that she was one of its longest-tenured participants. Since then, she has committed to sharing her experience with the brain cancer community and working towards increased funding for clinical research.

Registration is required. The Let’s Talk About Biomarker Testing: With MyTumorID, I Decide webinar will be hosted on Zoom. Login details will be sent in a confirmation email.